Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Coherus Oncology (CHRS) Debt to Equity (2016 - 2025)

Coherus Oncology's Debt to Equity history spans 12 years, with the latest figure at $0.61 for Q4 2025.

  • For Q4 2025, Debt to Equity rose 259.29% year-over-year to $0.61; the TTM value through Dec 2025 reached $0.61, up 259.29%, while the annual FY2025 figure was $0.61, 259.29% up from the prior year.
  • Debt to Equity for Q4 2025 was $0.61 at Coherus Oncology, up from $0.42 in the prior quarter.
  • Across five years, Debt to Equity topped out at $15.59 in Q1 2022 and bottomed at -$8.66 in Q2 2022.
  • The 5-year median for Debt to Equity is -$0.4 (2024), against an average of -$0.1.
  • The largest YoY upside for Debt to Equity was 2564.54% in 2022 against a maximum downside of 1906.39% in 2022.
  • A 5-year view of Debt to Equity shows it stood at $0.77 in 2021, then plummeted by 331.19% to -$1.79 in 2022, then increased by 27.71% to -$1.29 in 2023, then soared by 70.48% to -$0.38 in 2024, then skyrocketed by 259.29% to $0.61 in 2025.
  • Per Business Quant, the three most recent readings for CHRS's Debt to Equity are $0.61 (Q4 2025), $0.42 (Q3 2025), and $0.31 (Q2 2025).